EHA 2024 GMMG-HD7: Isatuximab plus lenalidomide, bortezomib, dexamethasone as induction therapy for transplant-eligible NDMM Admin July 1, 2024 Dr Fredrik Schjesvold, director of the Oslo Myeloma Center at the Oslo...